Holen Sie sich die Stockscreener-App
23.24
15.33%
3.09
Handel nachbörslich:
23.40
0.16
+0.69%
Schlusskurs vom Vortag:
$20.15
Offen:
$20.24
24-Stunden-Volumen:
6.64M
Relative Volume:
2.48
Marktkapitalisierung:
$14.86B
Einnahmen:
$956.00K
Nettoeinkommen (Verlust:
$-196.68M
KGV:
-96.83
EPS:
-0.24
Netto-Cashflow:
$-113.02M
1W Leistung:
+33.87%
1M Leistung:
+25.62%
6M Leistung:
+16.49%
1J Leistung:
+476.67%
1-Tages-Spanne:
$20.16
$23.31
1-Wochen-Bereich:
$15.55
$23.31
52-Wochen-Spanne:
$2.10
$33.89
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Vergleichen Sie SMMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
23.24 | 14.86B | 956.00K | -196.68M | -113.02M | -0.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.22 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.18 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.94 | 35.43B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.77 | 30.77B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
96.52 | 23.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX - MSN
Gold Related Large-Cap Stocks Outperformed In One Of The Most Volatile Weeks (Apr 7-Apr 11): Are These In Your Portfolio? - Benzinga
Why Summit Therapeutics Inc. (SMMT) Soared Last Week? - Insider Monkey
10 Firms Defy Market Slump, Record Double-Digit Gains Last Week - Insider Monkey
3 Magnificent Stocks That Could Double or More by 2030 - Yahoo Finance
Summit Therapeutics spikes after co-CEO’s early warrants exercise - MSN
Summit Therapeutics: Not Pharmacyclics, Not Yet - Seeking Alpha
Why Summit Therapeutics Inc. (SMMT) Surged On Friday? - MSN
Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks - Insider Monkey
U.S. Indexes Moved Upward Friday; Summit Therapeutics Led Increases - Barron's
Summit co-CEO option exercise ‘quite bullish,’ says Cantor Fitzgerald - Yahoo Finance
Expert says Summit’s HARMONi-2 study could beat expectations, says Truist - Yahoo Finance
Summit Therapeutics (SMMT) Grants Stock Options to New Employees - GuruFocus
Summit Therapeutics (SMMT) Shows Resilient Cash Management Amid Challenges - GuruFocus
Why Summit Therapeutics Inc. (SMMT) Went Up On Thursday? - Insider Monkey
Truist maintains Buy on Summit Therapeutics, $35 target By Investing.com - Investing.com South Africa
10 Firms Buck Thursday’s Market Bloodbath - Insider Monkey
Summit Therapeutics (SMMT) Shares Surge After Insider Actions - GuruFocus
Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets - MSN
Summit Therapeutics (SMMT) Sees Stock Surge Amid Early Warrant E - GuruFocus
Summit Therapeutics Shares Surge Amid Study Optimism - TipRanks
Summit Therapeutics (SMMT) Expected to Deliver Strong Results fr - GuruFocus
Summit Therapeutics (SMMT) Sees Bullish Surge as Co-CEO Exercise - GuruFocus
Summit Therapeutics stock gains on insider buy (SMMT:NASDAQ) - Seeking Alpha
Truist maintains Buy on Summit Therapeutics, $35 target - Investing.com
Cantor Fitzgerald maintains Overweight on Summit Therapeutics - Investing.com
Summit Therapeutics Co-CEOs Make Bold Stock Purchases! - TipRanks
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit - Yahoo Finance
Optimistic Buy Rating for Summit Therapeutics Driven by Promising HARMONi-2 Trial and Favorable Regulatory Pathway in China - TipRanks
2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade - Yahoo Finance
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Summit Therapeutics Inc.SMMT - MarketScreener
We Think Summit Therapeutics (NASDAQ:SMMT) Can Easily Afford To Drive Business Growth - Yahoo Finance
(SMMT) Technical Data - news.stocktradersdaily.com
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Summit Therapeutics Agrees to $127K Settlement in Wage Dispute - USA Herald
Summit Therapeutics Strengthens Team with Strategic Stock Options Worth $3.4M - Stock Titan
Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Summit Therapeutics (SMMT) Surpasses Nvidia with High Hopes for Cancer Drug - GuruFocus
3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months - Yahoo Finance
Chinese Biotech Eyes US Nod for Cancer Therapy Eluding Merck - Bloomberg.com
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today - Yahoo Finance
Virtu Financial LLC Cuts Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report? - Yahoo Finance
Summit Therapeutics: Major Upcoming Ivonescimab Data Catalyst May Not Be All It Seems (Rating Downgrade) - Seeking Alpha
Why Summit Therapeutics Stock Slipped Today - MSN
Summit Therapeutics (SMMT) Stock Movement Analysis - GuruFocus
Small cap wrap: Nano One Materials, EnWave, Summit Therapeutics... - Proactive Investors UK
Citigroup Upgrades Summit Therapeutics (BMV:SMMT) - Nasdaq
Summit Therapeutics stock rises on Citi upgrade (SMMT:NASDAQ) - Seeking Alpha
Summit Therapeutics rises as lead asset makes Citi its latest bull - MSN
Summit Therapeutics upgraded ahead of lung cancer trial data readout - Proactive financial news
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):